Since 2022, the healthcare industry in Russia has been affected by sweeping political and economic events. Some companies have left the market, others have changed the format of their presence, and others have seen new opportunities.

The regulator has piloted, introduced and cancelled various incentives, both positive and negative. However, such measures were often either a return to long-forgotten regulatory approaches or completely new solutions.

By early 2024, the situation has relatively stabilised. The government has developed a new approach to regulating and controlling the industry, and many of its players already have more or less sustainable plans for the future.

However, it is clear that the healthcare industry has not yet met all the challenges. It still has a long and winding road to go. To make it easier for you to navigate this journey, below is our overview of the main legal changes in the pharmaceutical and medical devices sector in 2023, including:

• Regulatory easing
• Extended and updated procedure for registration of medical devices
• Simpler EAEU requirements for drug registration
• New compulsory licence
• Problems with importing sanctioned goods
• Product labelling and online ad labelling
• Government control and other issues

The review is available in the handbook under the link.